Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Third party request |
| Strategy: | Prophylactic neutralizing Ab |
| Study Type: | Antibody Characterization |
| Species: | Human |
| Stage: | Assays completed |
| Study Start Date: | NA |
| Study Made Public: | NA |
Title
NA
Description
CAVD 871 (RiboMab_006) is a monoclonal antibody screening study evaluating in vitro produced CH1-CLx and CH1-CLcv CrossMab variants based on the broadly neutralizing antibodies (PGT121-LS, PGDM1400-LS, 10-1074-LS, 1-18-LS) in BioNTech’s RiboMab platform.
Sign in to see full information about this study and to download study data.
Products
No Products used in studyIntegrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.